Physician profile
Dennis Wayne Rowlen
NPI 1861565400
$1,570.82
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $761 · 2020: $226 · 2021: $236 · 2022: $347.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofire Diagnostics, LLC | $500.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $228.58 | 2019-2022 | |
| Tris Pharma INC | $206.01 | 2019-2022 | |
| Glaxosmithkline, LLC. | $182.40 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $122.34 | 2019-2022 | |
| Pfizer INC. | $61.02 | 2020-2021 | |
| Corium, LLC | $55.49 | 2022 | |
| Merck Sharp & Dohme LLC | $51.80 | 2021-2022 | |
| Sanofi Pasteur INC. | $49.29 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $42.51 | 2022 | |
| Neos Therapeutics, LP | $42.23 | 2019-2020 | |
| Seqirus USA INC | $17.81 | 2022 | |
| Almirall LLC | $11.34 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Rowlen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.